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Down-regulation of OPA1 in patients with primary open angle
glaucoma
Purpose: Heterozygous optic atrophy type1 (OPA1) mutations are responsible for dominant optic atrophy, and the down
regulation of OPA1 expression in patients with Leber hereditary optic neuropathy may imply that Opa1 protein levels in
mitochondria play a role in other spontaneous optic neuropathies as well. Mitochondrial and metabolic abnormalities may
put the optic nerve at risk in primary open angle glaucoma (POAG), and this preliminary study was designed to investigate
whether altered OPA1 expression might be present in the progressive optic neuropathy of POAG.
Methods: Patients were eligible for inclusion if they met standard clinical criteria for POAG, including age greater than
40 years, intraocular pressure ≥ 21 mmHg in at least one eye before treatment, normal-appearing anterior chamber angles
bilaterally on gonioscopy, and optic nerve injury characteristic of POAG. RNA was extracted from leukocytes and
converted to cDNA by reverse transcriptase enzyme, and real time PCR was used to assess expression levels of OPA1
and the β-globulin (HBB) housekeeping gene. The ratio of OPA1 expression to HBB expression (OPA1/HBB) for POAG
patients was compared to that of controls and to clinical characteristics of POAG patients.
Results: Forty-three POAG patients and 27 controls were completely phenotyped with a full ophthalmologic examination
and static perimetry. Mean age (POAG 67.9 years; controls 61.8 years) and sex (POAG 26 males/17 females; controls
11/16) were similar for the two groups. Mean OPA1/HBB of POAG patients (1.16, SD 0.26) was 18% lower than controls
(1.41, SD 0.50), and this difference was statistically significant (p≤0.021). OPA1 expression differed between the groups
(p≤0.037), but HBB expression did not differ (p≤0.24). OPA1/HBB was not correlated with any clinical feature of POAG
patients.
Conclusions:  Transcriptional  analysis  of  peripheral  blood  leucocytes  is  a  limited  model  system  for  studying  the
consequences of mitochondrial abnormalities in the optic nerve. Nevertheless, OPA1 is known to affect mitochondrial
stability and has now been implicated in several spontaneous optic neuropathies. Decreased OPA1 expression in POAG
patients is another indication that mitochondrial function, and possibly mitochondrially-induced apoptosis, may play a
role in the development of POAG.
Glaucoma  is  one  of  the  leading  causes  of  blindness
worldwide [1] with a prevalence of over 2% in individuals
older than 40 years [2]. Primary open angle glaucoma (POAG)
is the most common type of glaucoma in Western countries
and has risk factors that include elevated intraocular pressure
(IOP) and age [3], but these factors do not predict the presence
or degree of visual loss [4]. Up to half of all patients with
POAG have a positive family history, and the risk of POAG
is  increased  3–9  times  in  first-degree  relatives  of  POAG
patients [2,5]. In addition, a maternal family history of POAG
is 6–8 times more likely than a paternal family history [6-8].
These  observations  suggest  that  genetic  factors  may
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contribute to POAG, with a mitochondrial component being
particularly likely [1,9-11].
Mutations in the optic atrophy type1 (OPA1) gene are
unequivocally involved in the neuropathology of dominant
optic atrophy (DOA) [12,13]. The phenotype of DOA differs
from that of POAG, but DOA is sometimes misdiagnosed as
normal tension glaucoma in clinical practice [14]. In addition,
certain  OPA1  polymorphisms  have  been  linked  to  an
increased  risk  of  POAG  in  some,  but  not  all,  ethnic
populations [15-18] and with the normal tension variant of
POAG  [17,19].  Considered  together,  these  observations
suggest that OPA1 may be involved in the development of
POAG.
METHODS
Patients were evaluated in the Glaucoma Service at the Wills
Eye Institute and enrolled after examination by a glaucoma
specialist. Patients were eligible for inclusion if they met the
following clinical criteria for POAG [20-23]: age greater than
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College of Medicine, Jacksonville, FL40 years; intraocular pressure (IOP) ≥21 mmHg in one or both
eyes  before  initiation  of  glaucoma  treatment;  normal-
appearing,  open  anterior  chamber  angles  bilaterally  by
gonioscopy; optic nerve appearance characteristic of the optic
discs  typically  observed  in  primary  open-angle  glaucoma
(with localized narrowing or absence of the neuro- retinal rim,
with the amount of cupping exceeding the amount of pallor of
the rim, and with asymmetric cupping of the optic discs in the
two eyes); and static visual field (Humphrey Field Analyzer
II, Carl Zeiss Meditec, Inc., Dublin, CA; using a full threshold
24–2  program)  abnormalities  typical  of  glaucoma  (as  per
Advanced Glaucoma Intervention Study criteria [24]). There
had to be good agreement between the appearance of the optic
disc and the visual field. Exclusion criteria included historical,
neuroimaging, or biochemical evidence of another possible
optic  neuropathic  process  affecting  either  eye,  significant
visual loss in both eyes not associated with glaucoma, or
choosing not to participate. This research adhered to the tenets
of the Declaration of Helsinki, and all patients and controls
signed  an  informed  consent  approved  by  the  Wills  Eye
Institute institutional review board.
All control subjects (frequently spouses of patients) had
full ophthalmologic examinations and static perimetry. Each
had IOPs that were below 21 mmHg and symmetric in the two
eyes, normal anterior chambers, optic discs that were normal
and symmetric in appearance, entirely normal static perimetry
OU, and no prior history of glaucoma. All controls had static
perimetry performed in the same fashion as POAG patients.
A two-step semi-quantitative RT–PCR method was used
to measure gene expression levels of OPA1 and β-globulin
(HBB) in POAG patients and controls. Random hexameres
were used as primers in the first step of cDNA synthesis. Total
RNA (1 μg) was combined with 0.5 μg primers, 200 μM
dNTPs, and sterile Milli-Q water and preheated at 65 °C for
2 min to denature secondary structures. The mixture was then
cooled rapidly to 20 °C and then 10 μl 5× RT Buffer, 10 mM
dithiothreitol, and 200 U Moloney Murine Leukemia Virus
Reverse  Transcriptase  were  added  for  a  total  volume  of
50 μl. The RT mix was incubated at 37 °C for 90 min then
stopped by heating at 95 °C for 5 min. The cDNA stock was
stored at −20 °C.
Relative  RT–PCR  was  performed  to  measure  gene
expression  of  OPA1  and  HBB  according  to  standard
guidelines [25]. Primer sequences and optimal PCR annealing
temperatures (ta) are listed in Table 1. Primer sequences were
designed to span intron regions to insure that no false positive
PCR fragments would be generated from pseudogenes and
contaminate genomic DNA. In addition, all forward PCR
primers  were  labeled  with  fluorescein  (6-FAM),  making
quantitation more accurate. Polymerase chain reactions were
performed  using  100  ng  of  cDNA,  5  pmoles  of  each
oligonucleotide primer, 200 μM of each dNTP, 1 unit of
HotStar Taq-polymerase (Qiagen, Valencia, CA) and 1× PCR
buffer in a 20 μl volume. The PCR program initially started
with a 95 °C denaturation for 5 min, followed by 25 cycles of
95 °C for 1 min, ta °C for 45 s, and 72 °C for 1 min. Linear
amplification range for each gene was tested on the adjusted
cDNA,  and  25  cycles  were  found  to  be  optimal  for  both
OPA1 and HBB. The PCR samples were electrophoresed on
the 3130xl Genetic Analyzer (Applied Biosystems, Foster
City, CA). Figure 1 shows representative chromatograms for
a POAG patient and a control individual in which the size and
the  intensity  of  the  fluorescence  peaks  are  illustrated  for
OPA1 and HBB amplification.
The promoter region of the OPA1 gene was screened for
polymorphisms in all patients and controls using the forward
(5′-CCT TTC CCA TCT GAT CCT CA-3′) and reverse (5′-
CAG GAA TGA CCC AGG AAG TG-3′) primers to amplify
a region extending almost 700 bp immediately upstream of
the transcription initiation site, where the promoter region of
OPA1 is believed to be located [13].
Statistical analysis: Absolute RT–PCR values were used
to calculate a ratio of the OPA1 peak area in the selected linear
amplification cycle divided by that of HBB, creating an OPA1/
HBB ratio. All clinical and genetic data were analyzed using
SPSS v 16.02 (IBM Corporation, Somers, NY) and SAS v 9.2
(SAS Corporation, Cary, NC).
RESULTS
Age (POAG patients 67.0 years; controls 61.8 years; p≤0.06)
and sex (POAG 26 males/17 females; controls 11/16; p≤0.11)
of the 43 unrelated POAG patients were similar to the control
individuals, but ethnicity differed between the POAG group
(21 Caucasian/22 African American) and the control group
(23 Caucasian/4 African American; p≤0.002).
TABLE 1. PRIMER SEQUENCES AND ANNEALING TEMPERATURES.
Primer name Primer sequence Annealing temperature (°C)
HBB-F (6-FAM) AGC CTC GCC TTT GCC GA 57
HBB-R CTG GTG CCT GGG GCG  
OPA1-F (6-FAM) TGT GAG GTC TGC CAG TCT TTA 58
OPA1-R TGT CCT TAA TTG GGG TCG TTG  
               F=forward; R=reverse.
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in  POAG  patients  than  in  controls  (p≤0.037)  but  HBB
expression did not differ between the groups (p≤0.34; Table
2). The OPA1/HBB ratio was also significantly lower, by 18%,
in POAG patients than in controls (p≤0.021).
Differences in the OPA1/HBB ratio persisted even when
the evaluated groups were restricted to Caucasian patients and
controls (p≤0.04) to remove the potential effect of ethnic bias.
Similarly, mean OPA1 expression values were significantly
lower in Caucasian POAG patients than in Caucasian controls
(p=0.04),  but  HBB  expression  did  not  significantly  differ
between these groups (p≤0.34; Table 2).
Within the POAG group, the OPA1/HBB ratio was not
significantly associated with age, sex, ethnicity, visual acuity,
maximum  intraocular  pressure,  vertical  cup-to-disk  ratio,
static perimetry mean deviation, or static perimetry pattern
standard deviation (Table 3). However, power calculations
indicate  power  ≤80%  on  these  tests,  leaving  open  the
possibility of false negative type II statistical errors.
Neither POAG patients nor controls had polymorphisms
in the promoter region after reading and aligning all sequences
with  the  OPA1  promoter  reference  sequence  described
previously [13].
DISCUSSION
The 43 patients reported here met rigorous clinical criteria for
POAG [20-23] with elevated IOP, normal anterior chamber,
and  evidence  on  funduscopic  exam  and  visual  fields  of
glaucomatous  optic  nerve  damage.  They  did  not  have
evidence by clinical criteria of other types of glaucoma or
alternative  causes  of  optic  nerve  injury.  None  had
dysmorphism or an obvious genetic syndrome. They were
compared to 27 control individuals in whom POAG and other
evidence of optic nerve damage were carefully excluded.
OPA1 expression and the OPA1/HBB ratio were both
significantly lower in POAG patients than in controls (Table
2). POAG patients and controls were well matched for age and
sex. The POAG group included more African Americans than
the control group; however, OPA1 expression and OPA1/
HBB ratio were still significantly smaller in POAG patients
when both groups were restricted only to Caucasians. No
POAG  patient  had  a  mutation  or  polymorphism  of  the
Figure 1. Fluorescent PCR amplification. Capillary electrophoresis showing fluorescent PCR amplification of (A) the OPA1 gene (140 bp;
blue peak) and (B) the HBB gene (175 bp) for a POAG patient. Similarly, (C) shows OPA1 amplification and (D) shows HBB amplification
for a control individual. The x-axis represents peak size in base pairs (bp) and the y-axis the signal intensity. The area under the peak (not
shown here) corresponds to gene expression levels and was measured by the GeneMapper software (Applied Biosystems). Sizing of the peaks
was done by running the 500 pb LIZ size-ladder (peaks in orange) with the samples.
TABLE 2. GENE EXPRESSION IN POAG PATIENTS AND CONTROLS.
Measurement POAG mean Control mean p≤
OPA1 expression; mean (SD) 116714 (22220) 137761 (47076) 0.04
HBB expression; mean (SD) 104489 (33188) 98164 (7707) 0.24
OPA1/HBB; mean (SD) 1.16 (0.26) 1.41 (0.50) 0.02
OPA1 expression in Caucasians; mean (SD) 112979 (15699) 133460 (45261) 0.04
HBB expression in Caucasians; mean (SD) 108507 (47291) 98462 (7931) 0.34
OPA1/HBB in Caucasians; mean (SD) 1.12 (0.25) 1.37 (0.50) 0.04
               POAG=primary open angle glaucoma; SD=standard deviation.
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an alteration of expression.
Across all POAG patients, the OPA1/HBB ratio was not
correlated  with  any  demographic  measure  (e.g.,  age,  sex,
ethnicity, or age at diagnosis) or any standard measure of
POAG severity (e.g., visual acuity, vertical cup-to-disk ratio,
or measures of static perimetry abnormality; Table 3). The
results of this study, therefore, imply that decreased OPA1
expression, and possibly decreased Opa1 protein levels, may
contribute to the occurrence of POAG. They do not suggest
that OPA1 expression is related to POAG severity, although
this point may only be proven definitely by evaluating larger
numbers of patients for longer periods of time.
The  OPA1  gene  was  first  identified  as  the  gene
responsible for DOA [12,13] a decade ago. It codes for a
dynamin-like  GTPase  protein  (Opa1  protein)  found  in  a
polymeric structure in the inner mitochondrial membrane that
has  multiple  distinct  roles  [26,27]  primarily  related  to
maintaining a highly interconnected mitochondrial network
[28], regulating mitochondrial bioenergetic output through a
possible effect on the assembly and stability of Complex I and
IV  subunits  [29,30],  and  sequestering  pro-apoptotic  small
molecules within the mitochondrial cristae spaces [31,32].
Maintenance of mitochondrial DNA (mtDNA), at least in
certain settings [33], is a more recently recognized role.
OPA1  abnormalities  are  now  recognized  in  several
spontaneous optic neuropathies. Heterozygous mutations in
OPA1 are responsible for approximately 60% of DOA cases
[34,35], and it is possible that another 20% of DOA cases are
associated  with  large-scale  rearrangements  of  the  entire
OPA1  coding  region  [36].  We  reported  previously  that
OPA1 expression was decreased in patients with LHON and
the  11778  primary  LHON  mutation  [37].  Certain  OPA1
polymorphisms have been described in association with an
increased  risk  of  developing  POAG  or  normal  tension
glaucoma in some, but not all, populations studied [15-17].
The  results  of  this  study  raise  the  possibility  that
decreased OPA1 expression may play a role in in occurrence
of POAG in several ways. Down-regulation of OPA1 in HeLa
cells using specific small interfering RNA molecules caused
fragmentation of the mitochondrial network with dissipation
of  the  mitochondrial  membrane  potential  and  a  drastic
disorganization  of  the  cristae  [38].  These  changes  were
followed  by  cytochrome  c  release  and  caspase-dependent
apoptotic nuclear events. Mitochondria in this setting likely
do not produce energy optimally and may either cause or be
vulnerable  to  oxidative  stress  [39].  Decreased  OPA1
expression  in  POAG  patients  may  contribute  to  retinal
ganglion cell apoptosis as one primary mechanism of optic
nerve damage. Decreased ATP production and/or increased
oxidative stress may contribute to this process, particularly as
mitochondria work less well in an aging individual.
This study has several practical limitations. The number
of individuals studied was adequate to confirm statistically
significant differences in OPA1 expression and OPA1/HBB
ratio between POAG patients and controls. However, the lack
of correlation between OPA1/HBB ratio and various clinical
parameters within the POAG group may be subject to type II
statistical errors because of inadequate power. Transcriptional
analysis of peripheral blood leucocytes is not an ideal model
system for evaluating nuclear gene expression in optic nerve
tissue, which will rarely be available in glaucoma patients.
However,  peripheral  blood  cells  inherit  the  same  genetic
information  as  retinal  ganglion  cells,  and  leukocyte  gene
expression reflects pathologically important gene expression
TABLE 3. CORRELATION BETWEEN OPA1/HBB AND CLINICAL PARAMETERS
Parameter Value p≤
Age in years; mean (SD) 67.93 (10.55) 0.90
Sex (M:F) 26:17 0.10
Ethnicity (C:AA) 21:22 0.27
Visual acuity OD (mean) ~20/40 0.74
Visual acuity OS (mean) ~20/30 0.56
Maximum IOP OD (mmHg) 29.4 (6.3) 0.07
Maximum IOP OS (mmHg) 29.7 (6.9) 0.13
Vertical c/d ratio OD; mean (SD) 0.78 (0.21) 0.84
Vertical c/d ratio OS; mean (SD) 0.76 (0.20) 0.99
MD OD; mean (SD) −15.46 (10.28) 0.28
MD OS; mean (SD) −13.27 (10.37) 0.33
PSD OD; mean (SD) 7.52 (4.51) 0.74
PSD OS; mean (SD) 7.01 (4.33) 0.92
        SD=standard  deviation;  M=male;  F=female;  C=Caucasian;  AA=African  American;  OD=right  eye;  OS=left  eye;
        IOP=intraocular pressure; mmHg=mm mercury; c/d=cup to disk; MD=Humphrey visual field mean deviation; PSD=Humphrey
        visual field pattern standard deviation.
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population  studied  was  predominantly  Caucasian  and
African-American, and different results might be obtained in
other ethnicities.
The patients reported here have clinically definite POAG
with  a  modest,  statistically  significant  decrease  in  OPA1
expression even after normalization for expression of HBB, a
housekeeping  gene.  OPA1  plays  an  important  role  in
mitochondrial  structure  and  function,  including
mitochondrially-induced apoptosis. It has been implicated in
the  pathogenesis  of  several  other  spontaneous  optic
neuropathies, and this study suggests that OPA1 expression
may also play a role in the development of POAG. If these
results are confirmed in additional patient groups and other
ethnicities,  it  is  possible  that  methods  might  be  found  to
interfere  with  POAG  development  by  manipulation  of
OPA1 expression or other mitochondrial parameters.
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